{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:14:11Z","timestamp":1784042051422,"version":"3.55.0"},"reference-count":31,"publisher":"Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,22]]},"DOI":"10.31744\/einstein_journal\/2025ao1287","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:49:24Z","timestamp":1745416164000},"source":"Crossref","is-referenced-by-count":2,"title":["Dose-response relationships in Y90 resin microsphere radioembolization for patients with hepatocellular carcinoma: insights from a Brazilian cohort"],"prefix":"10.31744","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0886-8184","authenticated-orcid":false,"given":"Marcela Juliano Silva","family":"Cunha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3778","authenticated-orcid":false,"given":"Francisco Leonardo","family":"Galastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-2259","authenticated-orcid":false,"given":"Felipe","family":"Nasser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2940-9016","authenticated-orcid":false,"given":"Breno Boueri","family":"Affonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6255-340X","authenticated-orcid":false,"given":"Leonardo Guedes Moreira","family":"Valle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3063-9174","authenticated-orcid":false,"given":"Priscila Mina","family":"Falsarella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2297-504X","authenticated-orcid":false,"given":"Bruno Pagnin","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0223-7381","authenticated-orcid":false,"given":"Lilian Yuri Itaya","family":"Yamaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7654-9022","authenticated-orcid":false,"given":"Giovanna Sawaya","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-9595","authenticated-orcid":false,"given":"Rodrigo Gobbo","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1991-3507","authenticated-orcid":false,"given":"Nelson","family":"Wolosker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16942","reference":[{"issue":"3","key":"key20250423134916_B1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","unstructured":"1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"key20250423134916_B2","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-022-10392-y","article-title":"Simplification of dosimetry in 90 Y-radioembolization therapy by dual planar images","volume":"22","author":"Abuqbeitah","year":"2022","unstructured":"2. Abuqbeitah M, Akdag \u00d6T, Demir M, Asa S, S\u00f6nmezoglu K. Simplification of dosimetry in 90 Y-radioembolization therapy by dual planar images. BMC Cancer. 2022;22(1):1288.","journal-title":"BMC Cancer"},{"issue":"3","key":"key20250423134916_B3","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000528272","article-title":"IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study","volume":"12","author":"Kudo","year":"2022","unstructured":"3. Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, et al. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2022;12(3):238-50.","journal-title":"Liver Cancer"},{"issue":"37","key":"key20250423134916_B4","doi-asserted-by":"crossref","first-page":"5687","DOI":"10.3748\/wjg.v25.i37.5687","article-title":"Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging","volume":"25","author":"Affonso","year":"2019","unstructured":"4. Affonso BB, Galastri FL, Leal Filho JM, Nasser F, Falsarella PM, Cavalcante RN, et al. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging. World J Gastroenterol. 2019;25(37):5687-701.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"key20250423134916_B5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","unstructured":"5. Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681-93. Review.","journal-title":"J Hepatol"},{"issue":"12","key":"key20250423134916_B6","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","unstructured":"6. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aub\u00e9 C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624-36.","journal-title":"Lancet Oncol"},{"issue":"19","key":"key20250423134916_B7","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","article-title":"SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma","volume":"36","author":"Chow","year":"2018","unstructured":"7. Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, Choo SP, Cheow PC, Chotipanich C, Lim K, Lesmana LA, Manuaba TW, Yoong BK, Raj A, Law CS, Cua IHY, Lobo RR, Teh CSC, Kim YH, Jong YW, Han HS, Bae SH, Yoon HK, Lee RC, Hung CF, Peng CY, Liang PC, Bartlett A, Kok KYY, Thng CH, Low AS, Goh ASW, Tay KH, Lo RHG, Goh BKP, Ng DCE, Lekurwale G, Liew WM, Gebski V, Mak KSW, Soo KC; Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018;36(19):1913-21.","journal-title":"J Clin Oncol"},{"issue":"3","key":"key20250423134916_B8","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s00259-022-06002-5","article-title":"Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study","volume":"50","author":"Gregory","year":"2023","unstructured":"8. Gregory J, Tselikas L, Allimant C, de Baere T, Bargellini I, Bell J, et al. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study. Eur J Nucl Med Mol Imaging. 2023;50(3):921-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"key20250423134916_B9","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1148\/radiol.2020191606","article-title":"Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90 Y in the SARAH Study","volume":"296","author":"Hermann","year":"2020","unstructured":"9. Hermann AL, Dieudonn\u00e9 A, Ronot M, Sanchez M, Pereira H, Chatellier G, Garin E, Castera L, Lebtahi R, Vilgrain V; SARAH Trial Group. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with 90 Y in the SARAH Study. Radiology. 2020;296(3):673-84.","journal-title":"Radiology"},{"issue":"1","key":"key20250423134916_B10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","article-title":"Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial","volume":"6","author":"Garin","year":"2021","unstructured":"10. Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17-29.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"key20250423134916_B11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","unstructured":"11. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52-60.","journal-title":"Semin Liver Dis"},{"issue":"6","key":"key20250423134916_B12","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jhep.2011.03.007","article-title":"EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization","volume":"55","author":"Gillmore","year":"2011","unstructured":"12. Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309-16.","journal-title":"J Hepatol"},{"issue":"1","key":"key20250423134916_B13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4254\/wjh.v12.i1.21","article-title":"Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma","volume":"12","author":"Galastri","year":"2020","unstructured":"13. Galastri FL, Nasser F, Affonso BB, Valle LG, Od\u00edsio BC, Motta-Leal Filho JM, et al. Imaging response predictors following drug eluting beads chemoembolization in the neoadjuvant liver transplant treatment of hepatocellular carcinoma. World J Hepatol. 2020;12(1):21-33.","journal-title":"World J Hepatol"},{"key":"key20250423134916_B14","author":"National Cancer Institute (NCI)","year":"2017","unstructured":"14. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events (CTCAE). v5.0. 2017. Page 151 USA: NCI; 2027 [cited 2024 Dec 17]. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf","journal-title":"Common Terminology Criteria for Adverse Events (CTCAE)"},{"issue":"8","key":"key20250423134916_B15","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1007\/s00270-021-02834-0","article-title":"Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization","volume":"44","author":"Cheng","year":"2021","unstructured":"15. Cheng B, Villalobos A, Sethi I, Wagstaff W, Galt J, Brandon D, et al. Determination of Tumor Dose Response Thresholds in Patients with Chemorefractory Intrahepatic Cholangiocarcinoma Treated with Resin and Glass-based Y90 Radioembolization. Cardiovasc Intervent Radiol. 2021;44(8):1194-203.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"4","key":"key20250423134916_B16","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2967\/jnumed.111.097469","article-title":"Image-guided personalized predictive dosimetry by artery-specific SPECT\/CT partition modeling for safe and effective 90Y radioembolization","volume":"53","author":"Kao","year":"2012","unstructured":"16. Kao YH, Hock Tan AE, Burgmans MC, Irani FG, Khoo LS, Gong Lo RH, et al. Image-guided personalized predictive dosimetry by artery-specific SPECT\/CT partition modeling for safe and effective 90Y radioembolization. J Nucl Med. 2012;53(4):559-66.","journal-title":"J Nucl Med"},{"issue":"SEP","key":"key20250423134916_B17","article-title":"Determination of radiation absorbed dose to primary liver tumors and normal liver tissue using post radioembolization 90Y PET","volume":"4","author":"Srinivas","year":"2014","unstructured":"17. Srinivas SM, Natarajan N, Kuroiwa J, Gallagher S, Nasr E, Shah SN, et al. Determination of radiation absorbed dose to primary liver tumors and normal liver tissue using post radioembolization 90Y PET. Front Oncol. 2014;4(SEP):255.","journal-title":"Front Oncol"},{"issue":"12","key":"key20250423134916_B18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.jvir.2018.07.006","article-title":"Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma","volume":"29","author":"Allimant","year":"2018","unstructured":"18. Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, et al. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J Vasc Interv Radiol. 2018;29(12):1662-70.e4.","journal-title":"J Vasc Interv Radiol"},{"issue":"11","key":"key20250423134916_B19","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00270-022-03215-x","article-title":"Trans-arterial Radioembolization Dosimetry in 2022","volume":"45","author":"Garin","year":"2022","unstructured":"19. Garin E, Guiu B, Edeline J, Rolland Y, Palard X. Trans-arterial Radioembolization Dosimetry in 2022. Cardiovasc Intervent Radiol. 2022;45(11):1608-21. Review.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"10","key":"key20250423134916_B20","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","article-title":"A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study","volume":"49","author":"Lam","year":"2022","unstructured":"20. Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, et al. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340-52.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"key20250423134916_B21","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jvir.2023.03.011","article-title":"Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma","volume":"34","author":"Knight","year":"2023","unstructured":"21. Knight GM, Gordon AC, Gates V, Talwar A, Riaz A, Salem R, et al. Evolution of Personalized Dosimetry for Radioembolization of Hepatocellular Carcinoma. J Vasc Interv Radiol. 2023;34(7):1214-25. Review.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"key20250423134916_B22","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1007\/s00259-020-05163-5","article-title":"International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres","volume":"48","author":"Levillain","year":"2021","unstructured":"22. Levillain H, Bagni O, Deroose CM, Dieudonn\u00e9 A, Gnesin S, Grosser OS, et al. International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. Eur J Nucl Med Mol Imaging. 2021;48(5):1570-84.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"key20250423134916_B23","doi-asserted-by":"crossref","DOI":"10.1186\/s13550-022-00879-x","article-title":"Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC","volume":"12","author":"Veenstra","year":"2022","unstructured":"23. Veenstra EB, Ruiter SJ, de Haas RJ, Bokkers RP, de Jong KP, Noordzij W. Post-treatment three-dimensional voxel-based dosimetry after Yttrium-90 resin microsphere radioembolization in HCC. EJNMMI Res. 2022;12(1):9.","journal-title":"EJNMMI Res"},{"issue":"7","key":"key20250423134916_B24","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.jvir.2023.02.030","article-title":"Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres","volume":"34","author":"Villalobos","year":"2023","unstructured":"24. Villalobos A, Arndt L, Cheng B, Dabbous H, Loya M, Majdalany B, et al. Yttrium-90 Radiation Segmentectomy of Hepatocellular Carcinoma: A Comparative Study of the Effectiveness, Safety, and Dosimetry of Glass-Based versus Resin-Based Microspheres. J Vasc Interv Radiol. 2023;34(7):1226-34.","journal-title":"J Vasc Interv Radiol"},{"issue":"6","key":"key20250423134916_B25","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1007\/s00259-023-06111-9","article-title":"Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study","volume":"50","author":"Kokabi","year":"2023","unstructured":"25. Kokabi N, Arndt-Webster L, Chen B, Brandon D, Sethi I, Davarpanahfakhr A, et al. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study. Eur J Nucl Med Mol Imaging. 2023;50(6):1743-52.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"key20250423134916_B26","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030645","article-title":"For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT\/CT Predict Clinical Outcomes","volume":"15","author":"Taswell","year":"2023","unstructured":"26. Taswell CS, Studenski M, Pennix T, Stover B, Georgiou M, Venkat S, et al. For Hepatocellular Carcinoma Treated with Yttrium-90 Microspheres, Dose Volumetrics on Post-Treatment Bremsstrahlung SPECT\/CT Predict Clinical Outcomes. Cancers (Basel). 2023;15(3):645.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"key20250423134916_B27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12149-024-01926-4","article-title":"Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres","volume":"38","author":"Coskun","year":"2024","unstructured":"27. Coskun N, Kartal MO, Kartal AS, Cayhan V, Ozdemir M, Canyigit M, et al. Use of dose-volume histograms for metabolic response prediction in hepatocellular carcinoma patients undergoing transarterial radioembolization with Y-90 resin microspheres. Ann Nucl Med. 2024;38(7):525-33.","journal-title":"Ann Nucl Med"},{"issue":"1","key":"key20250423134916_B28","doi-asserted-by":"crossref","DOI":"10.1186\/s40658-022-00520-9","article-title":"Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma","volume":"10","author":"Orcajo Rinc\u00f3n","year":"2023","unstructured":"28. Orcajo Rinc\u00f3n J, Regi AR, Pe\u00f1a AM, Berenguer LR, Leyte MG, Mart\u00edn LC, et al. Maximum tumor-absorbed dose measured by voxel-based multicompartmental dosimetry as a response predictor in yttrium-90 radiation segmentectomy for hepatocellular carcinoma. EJNMMI Phys. 2023; 10(1):7.","journal-title":"EJNMMI Phys"},{"issue":"7","key":"key20250423134916_B29","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jvir.2018.03.018","article-title":"Radioembolization for Hepatocellular Carcinoma: a Nationwide 10-Year Experience","volume":"29","author":"Tohme","year":"2018","unstructured":"29. Tohme S, Bou Samra P, Kaltenmeier C, Chidi AP, Varley PR, Tsung A. Radioembolization for Hepatocellular Carcinoma: a Nationwide 10-Year Experience. J Vasc Interv Radiol. 2018;29(7):912-9.e2.","journal-title":"J Vasc Interv Radiol"},{"issue":"14","key":"key20250423134916_B30","doi-asserted-by":"crossref","first-page":"13017","DOI":"10.1007\/s00432-023-05185-0","article-title":"Post-therapeutic microRNA-146a in liquid biopsies may determine prognosis in metastatic gastrointestinal cancer patients receiving 90 Y-radioembolization","volume":"149","author":"Hirner-Eppeneder","year":"2023","unstructured":"30. Hirner-Eppeneder H, \u00d6cal E, Stechele M, \u00d6cal O, Gu S, Kimm MA, et al. Post-therapeutic microRNA-146a in liquid biopsies may determine prognosis in metastatic gastrointestinal cancer patients receiving 90 Y-radioembolization. J Cancer Res Clin Oncol. 2023;149(14):13017-26.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"65","key":"key20250423134916_B31","doi-asserted-by":"crossref","first-page":"32523","DOI":"10.18632\/oncotarget.25992","article-title":"Genomic mutations and histopathologic biomarkers in Y 90 radioembolization for chemorefractory colorectal liver metastases","volume":"9","author":"Dendy","year":"2018","unstructured":"31. Dendy MS, Ludwig JM, Kokabi N, Stein SM, Lacy J, Hochster HS, et al. Genomic mutations and histopathologic biomarkers in Y 90 radioembolization for chemorefractory colorectal liver metastases. Oncotarget. 2018;9(65): 32523-33.","journal-title":"Oncotarget"}],"container-title":["einstein (S\u00e3o Paulo)"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T13:49:29Z","timestamp":1745416169000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.einstein.br\/article\/dose-response-relationships-in-y90-resin-microsphere-radioembolization-for-patients-with-hepatocellular-carcinoma-insights-from-a-brazilian-cohort\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":31,"alternative-id":["10.31744\/einstein_journal\/2025AO1287"],"URL":"https:\/\/doi.org\/10.31744\/einstein_journal\/2025ao1287","relation":{},"ISSN":["1679-4508","2317-6385"],"issn-type":[{"value":"1679-4508","type":"print"},{"value":"2317-6385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"eAO1287"}}